Saima Aslam1, Jinyuan Liu1, Rachel Sigler1, Rehan R Syed1, Xin M Tu1, Susan J Little1, Victor De Gruttola2. 1. Department of Medicine, Division of Infectious Diseases and Global Public Health, University of California San Diego, La Jolla, California, USA. 2. Department of Biostatistics, Harvard TH Chan School of Public Health, Harvard University, Boston, Massachusetts, USA.
Abstract
BACKGROUND: Clinical effectiveness of coronavirus disease 2019 (COVID-19) vaccination in solid organ transplant recipients (SOTRs) is not well documented despite multiple studies demonstrating sub-optimal immunogenicity. METHODS: We reviewed medical records of eligible SOTRs at a single center to assess vaccination status and identify cases of symptomatic COVID-19 from January 1 to August 12, 2021. We developed a Cox proportional hazards model using the date of vaccination and time since transplantation as a time-varying covariate with age and gender as potential time-invariant confounders. Survival curves were created using the parameters estimated from the Cox model. RESULTS: Among 1904 SOTRs, 1362 were fully vaccinated (96% received mRNA vaccines) and 542 were either unvaccinated (n = 470) or partially vaccinated (n = 72). There were 115 cases of COVID-19, of which 12 occurred in fully vaccinated individuals. Cox regression with the date of vaccination and time since transplantation as the time-varying co-variates showed that after baseline adjustment for age and sex, being fully vaccinated had a significantly lower hazard for COVID-19, hazard ratio (HR) = 0.29 and 95% confidence interval ([CI] 0.09, 0.91). CONCLUSION: We found that 2-dose mRNA COVID-19 vaccination was protective of symptomatic COVID-19 in vaccinated versus unvaccinated SOTRs. TWEET: COVID-19 vaccination was associated with a significantly lower hazard for symptomatic COVID-19 (HR 0.29; 95% CI 0.09, 0.91) among 1904 SOT recipients at a single center from January 1 to August 12, 2021.
BACKGROUND: Clinical effectiveness of coronavirus disease 2019 (COVID-19) vaccination in solid organ transplant recipients (SOTRs) is not well documented despite multiple studies demonstrating sub-optimal immunogenicity. METHODS: We reviewed medical records of eligible SOTRs at a single center to assess vaccination status and identify cases of symptomatic COVID-19 from January 1 to August 12, 2021. We developed a Cox proportional hazards model using the date of vaccination and time since transplantation as a time-varying covariate with age and gender as potential time-invariant confounders. Survival curves were created using the parameters estimated from the Cox model. RESULTS: Among 1904 SOTRs, 1362 were fully vaccinated (96% received mRNA vaccines) and 542 were either unvaccinated (n = 470) or partially vaccinated (n = 72). There were 115 cases of COVID-19, of which 12 occurred in fully vaccinated individuals. Cox regression with the date of vaccination and time since transplantation as the time-varying co-variates showed that after baseline adjustment for age and sex, being fully vaccinated had a significantly lower hazard for COVID-19, hazard ratio (HR) = 0.29 and 95% confidence interval ([CI] 0.09, 0.91). CONCLUSION: We found that 2-dose mRNA COVID-19 vaccination was protective of symptomatic COVID-19 in vaccinated versus unvaccinated SOTRs. TWEET: COVID-19 vaccination was associated with a significantly lower hazard for symptomatic COVID-19 (HR 0.29; 95% CI 0.09, 0.91) among 1904 SOT recipients at a single center from January 1 to August 12, 2021.
Authors: Madeleine R Heldman; Olivia S Kates; Kassem Safa; Camille N Kotton; Sarah J Georgia; Julie M Steinbrink; Barbara D Alexander; Marion Hemmersbach-Miller; Emily A Blumberg; Ashrit Multani; Brandy Haydel; Ricardo M La Hoz; Lisset Moni; Yesabeli Condor; Sandra Flores; Carlos G Munoz; Juan Guitierrez; Esther I Diaz; Daniela Diaz; Rodrigo Vianna; Giselle Guerra; Matthias Loebe; Robert M Rakita; Maricar Malinis; Marwan M Azar; Vagish Hemmige; Margaret E McCort; Zohra S Chaudhry; Pooja P Singh; Kailey Hughes Kramer; Arzu Velioglu; Julie M Yabu; Jose A Morillis; Sapna A Mehta; Sajal D Tanna; Michael G Ison; Ariella C Derenge; David van Duin; Adrienne Maximin; Carlene Gilbert; Jason D Goldman; Erika D Lease; Cynthia E Fisher; Ajit P Limaye Journal: Am J Transplant Date: 2021-10-07 Impact factor: 9.369
Authors: Brian J Boyarsky; William A Werbel; Robin K Avery; Aaron A R Tobian; Allan B Massie; Dorry L Segev; Jacqueline M Garonzik-Wang Journal: JAMA Date: 2021-06-01 Impact factor: 56.272
Authors: Victoria G Hall; Victor H Ferreira; Terrance Ku; Matthew Ierullo; Beata Majchrzak-Kita; Cecilia Chaparro; Nazia Selzner; Jeffrey Schiff; Michael McDonald; George Tomlinson; Vathany Kulasingam; Deepali Kumar; Atul Humar Journal: N Engl J Med Date: 2021-08-11 Impact factor: 91.245
Authors: Jocelyn Keehner; Lucy E Horton; Nancy J Binkin; Louise C Laurent; David Pride; Christopher A Longhurst; Shira R Abeles; Francesca J Torriani Journal: N Engl J Med Date: 2021-09-01 Impact factor: 91.245
Authors: Nassim Kamar; Florence Abravanel; Olivier Marion; Chloé Couat; Jacques Izopet; Arnaud Del Bello Journal: N Engl J Med Date: 2021-06-23 Impact factor: 91.245
Authors: Jason M Duran; Masihullah Barat; Andrew Y Lin; Kevin R King; Barry Greenberg; Eric D Adler; Saima Aslam Journal: Clin Transplant Date: 2021-12-13 Impact factor: 3.456
Authors: Donald J Alcendor; Patricia Matthews-Juarez; Duane Smoot; James E K Hildreth; Kimberly Lamar; Mohammad Tabatabai; Derek Wilus; Paul D Juarez Journal: Vaccines (Basel) Date: 2022-05-11
Authors: Matthaios Papadimitriou-Olivgeris; Ana Cipriano; Nicolas Guggisberg; Marie Kroemer; Jonathan Tschopp; Oriol Manuel; Dela Golshayan Journal: Transpl Int Date: 2022-10-04 Impact factor: 3.842